Hematology

FDA panel votes in favor of belantamab mafodotin for relapsed/refractory myeloma

The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in favor of monotherapy treatment with belantamab mafodotin for patients with relapsed or refractory multiple myeloma concluding that the benefits outweigh potential risks, according to a press release. Adverse events, including keratopathy were noted in a...